Apimeds Pharmaceuticals US (APUS) Liabilities and Shareholders Equity (2023 - 2025)

Apimeds Pharmaceuticals US has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $164.2 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 1257338.43% year-over-year to $164.2 million; the trailing twelve-month figure through Dec 2025 stood at $184.2 million (up 1410946.62% YoY), and the FY2025 full-year result was $164.2 million, up 1257338.43% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $164.2 million, up from $9.3 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $164.2 million in Q4 2025, with the low at $13057.0 in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $30.8 million across 3 years, with a median of $4.8 million in 2023.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity sank 96.91% — and 2025, when it surged 1257338.43%.
• Apimeds Pharmaceuticals US's Liabilities and Shareholders Equity stood at $422076.0 in 2023, then slumped by 96.91% to $13057.0 in 2024, then surged by 1257338.43% to $164.2 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $164.2 million (Q4 2025), $9.3 million (Q3 2025), and $10.5 million (Q2 2025), per Business Quant data.